Centessa Pharmaceuticals (NASDAQ:CNTA) Posts Earnings Results

Centessa Pharmaceuticals (NASDAQ:CNTA) released its earnings results on Tuesday. The company reported ($0.52) EPS for the quarter, FiscalAI reports.

Centessa Pharmaceuticals Trading Down 0.1%

Shares of NASDAQ:CNTA traded down $0.05 on Wednesday, hitting $39.62. The company had a trading volume of 555,320 shares, compared to its average volume of 2,335,654. The firm’s 50-day simple moving average is $33.17 and its two-hundred day simple moving average is $27.94. The firm has a market capitalization of $5.91 billion, a price-to-earnings ratio of -26.95 and a beta of 1.13. The company has a quick ratio of 8.57, a current ratio of 8.57 and a debt-to-equity ratio of 0.21. Centessa Pharmaceuticals has a 1 year low of $10.95 and a 1 year high of $40.26.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Wolfe Research lowered Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday, March 31st. TD Cowen reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 14th. Piper Sandler reaffirmed an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Wells Fargo & Company lowered shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $35.00 to $42.00 in a report on Monday, April 20th. Finally, Truist Financial lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price for the company. in a report on Monday, April 13th. Four analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $40.70.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 120,029 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.25, for a total value of $3,150,761.25. Following the completion of the sale, the insider directly owned 62,085 shares in the company, valued at $1,629,731.25. This trade represents a 65.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Gregory M. Weinhoff sold 73,196 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider owned 65,925 shares in the company, valued at $1,735,805.25. This trade represents a 52.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 309,112 shares of company stock valued at $8,424,535. 7.09% of the stock is owned by insiders.

Institutional Trading of Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. TD Waterhouse Canada Inc. purchased a new position in Centessa Pharmaceuticals during the fourth quarter valued at $25,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Centessa Pharmaceuticals in the 4th quarter worth about $36,000. T. Rowe Price Investment Management Inc. increased its stake in Centessa Pharmaceuticals by 7,580.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after purchasing an additional 1,516 shares in the last quarter. Wells Fargo & Company MN raised its holdings in Centessa Pharmaceuticals by 42.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after buying an additional 1,008 shares during the last quarter. Finally, Knott David M Jr bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth approximately $100,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.